BiotechTube

xylo+dex nasal spray (0.1 mg+5 mg/dose) + Nasic

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nasal Congestion

Conditions

Nasal Congestion

Trial Timeline

Feb 26, 2018 → May 2, 2018

NCT ID
NCT03439436

About xylo+dex nasal spray (0.1 mg+5 mg/dose) + Nasic

xylo+dex nasal spray (0.1 mg+5 mg/dose) + Nasic is a phase 3 stage product being developed by Johnson & Johnson for Nasal Congestion. The current trial status is completed. This product is registered under clinical trial identifier NCT03439436. Target conditions include Nasal Congestion.

What happened to similar drugs?

8 of 20 similar drugs in Nasal Congestion were approved

Approved (8) Terminated (3) Active (11)
✅Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mgJohnson & JohnsonApproved
✅Budesonide NasalJohnson & JohnsonApproved
✅mometasone furoateMerckApproved
✅Dupilumab SAR231893SanofiApproved
✅DupilumabSanofiApproved
✅Dupilumab + Omalizumab + PlaceboSanofiApproved
✅Dupilumab Prefilled SyringeRegeneron PharmaceuticalsApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03439436Phase 3Completed

Competing Products

20 competing products in Nasal Congestion

See all competitors
ProductCompanyStageHype Score
Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + DexamethasoneEli LillyPhase 2
31
Rabeprazole 20 mg twice a day for 90-day period treatmentEisaiPhase 2
35
High dose of methotrexate + Gemcitabine + Pegaspargase + DexamethasoneEli LillyPhase 2
31
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
47
Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mgJohnson & JohnsonApproved
43
Budesonide NasalJohnson & JohnsonApproved
47
Diphenhydramine hydrochlorideJohnson & JohnsonPhase 1
29
SHR-1210Jiangsu Hengrui MedicinePhase 2
31
Experimental: Tezepelumab + Mometasone furoate or equivalent intranasal corticosteroidAstraZenecaPhase 3
40
Benralizumab 30 mg + Matched placeboAstraZenecaPhase 3
32
Benralizumab 30 mg SC + Mometasone Furoate + Matching placebo SC + Mometasone FuroateAstraZenecaPhase 3
40
Benralizumab + PlaceboAstraZenecaPhase 3
40
Pembrolizumab + Cisplatin + Docetaxel + CarboplatinMerckPhase 2
42
mometasone furoateMerckApproved
35
Fevipiprant 150 mg + Fevipiprant 450 mg + PlaceboNovartisPhase 3
40
Omalizumab + PlaceboNovartisPhase 2
35
Omalizumab + PlaceboRochePhase 3
40
Omalizumab + PlaceboRochePhase 3
40
Omalizumab + PlaceboRochePhase 3
40
carfilzomibAmgenPhase 1
29